Key facts
- This page summarizes Peter A. Thompson's Form 4 filing for Aspen Neuroscience, Inc. (ASPE).
- 11 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 04 Nov 2026, 18:47.
Peter A. Thompson - 02 Nov 2026 Form 4 Insider Report for Aspen Neuroscience, Inc. (ASPE)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- ASPE
- Reported as of
- 02 Nov 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Nov 2026, 18:47:25 UTC
- Prior SEC filing
- 29 Oct 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter A. Thompson
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Peter A. Thompson filed Form 4 for Aspen Neuroscience, Inc. (ASPE) on 04 Nov 2026.
Change
- Previous filing in this sequence was filed on 29 Oct 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001357522
Primary reporting owner
Thompson Peter A.
- Relationship
- Director, 10%+ Owner
- Address
- C/O ASPEN NEUROSCIENCE, INC., 10835 ROAD TO THE CURE, SUITE 100, SAN DIEGO
- Signature
- /s/ Peter A. Thompson
- Signature date
- 04 Nov 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ASPE
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +196,541
- Change %
- Price
- Shares after
- 196,541
- Date
- 02 Nov 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F4
ASPE
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +642,745
- Change %
- +327%
- Price
- Shares after
- 839,286
- Date
- 02 Nov 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F4
ASPE
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +616,984
- Change %
- +74%
- Price
- Shares after
- 1,456,270
- Date
- 02 Nov 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F4
ASPE
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +625,743
- Change %
- +43%
- Price
- Shares after
- 2,082,013
- Date
- 02 Nov 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F4
ASPE
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +507,119
- Change %
- +24%
- Price
- Shares after
- 2,589,132
- Date
- 02 Nov 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F4
ASPE
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +1,000,000
- Change %
- +39%
- Price
- $15.00*
- Shares after
- 3,589,132
- Date
- 02 Nov 2026
- Ownership
- See footnotes
- Footnotes
- F2, F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ASPE
transaction
Derivative
Series Seed-2 Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -196,541
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 02 Nov 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 196,541
- Exercise price
- Footnotes
- F1, F3, F4
ASPE
transaction
Derivative
Series A-1 Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -642,745
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 02 Nov 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 642,745
- Exercise price
- Footnotes
- F1, F3, F4
ASPE
transaction
Derivative
Series A-2 Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -616,984
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 02 Nov 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 616,984
- Exercise price
- Footnotes
- F1, F3, F4
ASPE
transaction
Derivative
Series B Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -625,743
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 02 Nov 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 625,743
- Exercise price
- Footnotes
- F1, F3, F4
ASPE
transaction
Derivative
Series C Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -507,119
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 02 Nov 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 507,119
- Exercise price
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Pursuant to the Issuer's Amended and Restated Certificate of Incorporation, as amended, each share of Series Seed-2 Convertible Preferred Stock, Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock, and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Preferred Stock automatically converted on a 1-for-9.8821 basis into shares of Common Stock, for no additional consideration. Share numbers give effect to such conversion. The securities have no expiration date.
Footnote F2
Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
Footnote F3
Securities held by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII, except to the extent of its or his pecuniary interest therein if any.
Footnote F4
Each of the Reporting Person, OrbiMed Advisors, and OrbiMed GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or OrbiMed GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.